ESR1 and prostate carcinoma: Direct regulator of androgen receptor levels in prostate cancer. Its expression is lower in ERα-positive breast tumors vs. ERα-negative samples, since ERα is a direct target of the miRNA. miR-135b also inhibits the HIF1α.